VALITUDE (Model U125); VALITUDE X4 (Model U128); VISIONIST (Models U225, U226); VISIONIST X4 (Model U228)
Guidant Corp. · Decision date Oct 3, 2026
What did the FDA decide?
This 30-day notice for P030005/S257 records a process change for Guidant Corp. pacemaker and CRT-P models. The stated purpose is to add an acceptance activity for Accolade SL batteries and to change a specification for an existing Accolade EL battery specification.
The supplement type is a process change involving manufacturer, sterilizer, packager, or supplier. The decision field reads OK30. The source statement does not describe any clinical testing, safety data, or effectiveness evidence, and it does not identify which specification changed or what the new acceptance activity entails.
FDA approval order statement
to implement an additional acceptance activity for Accolade SL batteries and to change a specification for an existing Accolade EL battery specification
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 3, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030005/S257
- Regulatory pathway
- PMA supplement
- Applicant
- Guidant Corp.
- Product code
- NKE
- Decision code
- OK30
- Decision date
- Oct 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).
- Applicant
- Guidant Corp.
- Product code
- NKE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030005. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030005 · Original PMA
CONTAK RENEWAL MODELS H125 AND H120 WITH THE MODEL 2865 VERSION 1.8 APPLICATION SOFTWARE
P030005/S257 received
Application receipt date recorded by FDA.
P030005/S257 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P030005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Guidant Corp. | PMA approval | Jan 26, 2004 | FDA |
Explore the linked device profile
Other records with product code NKE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP070008/S177 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Guidant Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: P030005/S257
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



